All sponsors

Tango Therapeutics, Inc. $TNGX

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING3
READOUTS ≤12 MONTHS3
Open Tango Therapeutics, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
TNG260
NCT05887492
P1/2Active, not recruitingNon Small Cell Lung Cancer; Solid Tumors, Adult1262026-09 (+20 mo)
TNG456
NCT06810544
P1/2RecruitingNon Small Cell Lung Cancer; Glioma Glioblastoma Multiforme1912027-03-31
TNG462
NCT05732831
P1/2RecruitingLocally Advanced Solid Tumor2252027-06 (+13 mo)
TNG462
NCT06922591
P1/2RecruitingPDAC; PDAC - Pancreatic Ductal Adenocarcinoma1832027-06
vopimetostat
NCT07897734
P1/2Not yet recruitingPDAC; PDAC - Pancreatic Ductal Adenocarcinoma1882031-11